Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review
- PMID: 29251034
- DOI: 10.1080/14397595.2017.1416940
Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review
Abstract
Objectives: To identify, describe and summarize evidence on residual symptoms and disease burdens in rheumatoid arthritis (RA) patients qualified as being in remission or low disease activity (LDA).
Methods: A systematic literature review (SLR) was conducted according to Cochrane collaboration guidelines. The population of interest was adult patients with RA in remission or LDA. The reported outcomes of interest were any symptoms or burdens.
Results: Fifty-one publications were identified through an eDatabase search. Together with 17 articles found through other sources, 68 were included for full text review. The most commonly reported residual symptoms were pain (number of studies = 25), fatigue (n = 21) and morning stiffness (n = 5). Reported disease burdens included mental health (n = 15), sleep disturbances (n = 7) and work productivity (n = 5), impairment in quality of life (n = 21), and functional disability (n = 34). Substantial residual symptoms and disease burdens were found to be present in patients in remission or LDA.
Conclusion: This is the first SLR to investigate residual symptoms and disease burdens in RA patients in remission or LDA. The results indicate that despite achieving conventional clinical targets, the disease continues to affect patients, suggesting the existence of unmet need under the current treatment paradigm.
Keywords: Low disease activity; remission; residual symptom; rheumatoid arthritis; systematic literature review.
Similar articles
-
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420. Health Technol Assess. 2006. PMID: 17049139
-
What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis.Health Technol Assess. 2018 Apr;22(20):1-258. doi: 10.3310/hta22200. Health Technol Assess. 2018. PMID: 29712616 Free PMC article.
-
The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.Health Technol Assess. 2004 Mar;8(11):iii, 1-91. doi: 10.3310/hta8110. Health Technol Assess. 2004. PMID: 14982655
-
The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. doi: 10.3310/hta8180. Health Technol Assess. 2004. PMID: 15130461
-
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2. Cochrane Database Syst Rev. 2021. PMID: 34844288 Free PMC article.
Cited by
-
Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction.RMD Open. 2021 Apr;7(1):e001566. doi: 10.1136/rmdopen-2021-001566. RMD Open. 2021. PMID: 33811177 Free PMC article.
-
Newly diagnosed with inflammatory arthritis (NISMA)-development of a complex self-management intervention.BMC Health Serv Res. 2023 Feb 7;23(1):123. doi: 10.1186/s12913-022-09007-w. BMC Health Serv Res. 2023. PMID: 36750937 Free PMC article.
-
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.RMD Open. 2022 Mar;8(1):e001994. doi: 10.1136/rmdopen-2021-001994. RMD Open. 2022. PMID: 35264432 Free PMC article. Clinical Trial.
-
Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study.J Cannabis Res. 2022 Aug 24;4(1):47. doi: 10.1186/s42238-022-00154-9. J Cannabis Res. 2022. PMID: 35999581 Free PMC article.
-
Cannabis and Cannabinoids in the Treatment of Rheumatic Diseases.Rambam Maimonides Med J. 2020 Jan 30;11(1):e0007. doi: 10.5041/RMMJ.10389. Rambam Maimonides Med J. 2020. PMID: 32017684 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical